In particular, 100 % of pancreas and vulva tumors, 90 % of breast tumors, 71 % of melanomas, and 70 % of ovary and small intestine tumors showed a significant decrease of eIF3f expression [55]. This evidence concerns the gene EIF3F and melanoma.